Spark Therapeutics (ONCE) Tops Q4 EPS by 49c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Spark Therapeutics Reports 2015 Financial Results and Business Highlights
March 9, 2016 8:02 AM ESTFollowing positive top-line results from pivotal Phase 3 trial of SPK-RPE65 for genetic blinding conditions, company significantly expands and advances gene therapy pipeline
Begins 2016 with a cash position over $300 million
PHILADELPHIA, March 09, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE) today announced financial results for the year ended December 31, 2015 and updated investors on its operational progress. The company highlighted advances made throughout 2015 in establishing its gene therapy platform and robust pipeline.
This past year was one of significant growth, progress and... More
